Personalized vaccine shows promise against aggressive brain cancer (glioblastoma). People in early clinical trial had increased immune response, slowed tumor progression. The vaccine caused no serious side effects. One long-term survivor remains recurrence-free nearly five years later.

Personalized vaccine shows promise against aggressive brain cancer (glioblastoma). People in early clinical trial had increased immune response, slowed tumor progression. The vaccine caused no serious side effects. One long-term survivor remains recurrence-free nearly five years later.